Estrella Immunopharma’s decision to advance EB103 into dose-expansion is based on a strategically opaque signal, rendering any external validation of its 'promising' nature impossible. The company reports maintained complete responses (CRs) at six months from the STARLIGHT-1 dose-escalation phase—a qualitatively positive sign suggesting potential durability. However, the complete absence of information on EB103's mechanism of action, molecular target, and modality prevents any meaningful comparison to the crowded field of B-cell NHL therapies. Without knowing if EB103 is an ADC, a bispecific, a CAR-T, or a novel small molecule, it cannot be benchmarked against established players like Polivy or Lunsumio, or emerging agents. Furthermore, the company has not disclosed the number of patients treated or the actual CR rate, making it impossible to assess the magnitude of the effect. The r/r NHL regulatory landscape has a rising evidentiary bar, increasingly favoring randomized data. While accelerated approval precedents exist for single-arm trials with high, durable response rates, EB103's undisclosed data package offers no basis to assume it can meet this standard. The critical, unresolvable risk is that EB103's potential remains entirely speculative until its mechanism and quantified efficacy data are revealed.
The verdict rests on unquantified efficacy claims from a Phase I, open-label, single-arm dose-escalation cohort. Without the mechanism, patient numbers, or response rates, the data lacks the context required for validation. [1]
| Indication | relapsed or refractory B-cell non-Hodgkin’s lymphoma |
| Drug | EB103 |
| Mechanism of Action | CD19-redirected ARTEMIS T-cell therapy |
| Company | Estrella Immunopharma |
| Trial Phase | Phase I/II |
| Trial Acronym | STARLIGHT-1 |
| Category | Clinical Trial Event |
| Sub Category | Patient Enrollment Milestone |
| Therapeutic Area | Oncology |
| Patient Population | Adults with relapsed or refractory B-cell non-Hodgkin’s lymphoma |
| Trial Design | Multi-centre, open-label |
| Trial Sites | Baylor Scott & White Research Institute, UC Davis Comprehensive Cancer Center |
| Technology | ARTEMIS technology |
| Technology Licensor | Eureka Therapeutics |
| Target Antigen | CD19 |
| Phase I Outcome | Sustained complete responses at six-month evaluation for patients without central nervous system involvement |
| CEO | Cheng Liu |
Estrella Doses First Patient in STARLIGHT-1 Dose-Expansion Cohort
Estrella Immunopharma has dosed the first patient in the dose-expansion segment of its STARLIGHT-1 Phase I/II trial, evaluating EB103 for relapsed or refractory (r/r) B-cell non-Hodgkin’s lymphoma (NHL). This advancement follows promising earlier findings from the dose-escalation stage, where patients achieved and maintained complete response status at the six-month evaluation, particularly those without central nervous system involvement. The multi-centre, open-label trial aims to further investigate EB103’s safety and efficacy at the recommended Phase II dose in adult patients.
- The STARLIGHT-1 trial has successfully transitioned to its dose-expansion cohort, building on positive data from the dose-escalation stage. In the earlier phase, patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma who achieved a complete response at the six-month evaluation, and did not have central nervous system involvement, maintained this complete response status.
- EB103 is characterized as a Cluster of Differentiation 19 (CD19)-redirected ARTEMIS T-cell therapy. This innovative technology, licensed from Estrella’s parent company Eureka Therapeutics, is engineered to activate and regulate T-cells upon engaging with cancer targets, mimicking endogenous T-cell receptor mechanisms to specifically bind and destroy CD19-positive cancer cells.
- The ongoing multi-centre, open-label STARLIGHT-1 trial is designed to thoroughly assess the safety and efficacy of EB103 at its recommended Phase II dose in patients aged 18 years and older with r/r B-cell NHL. The data collected from this expansion cohort will be crucial in shaping the strategic direction for any subsequent pivotal trials involving EB103.
The Persistent Challenges in Treating Relapsed/Refractory B-cell NHL
Despite advances in immunochemotherapy, targeted agents, and cellular therapies, relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) remains a therapeutic challenge, with a substantial subset of patients experiencing treatment failure and poor long-term outcomes. Resistance mechanisms across multiple drug classes, incomplete understanding of immune-related treatment failure, and safety/tolerability concerns with continuous oral therapies collectively constrain durable disease control.
Unfavourable prognosis and limited options: Patients with R/R B-cell NHL continue to face a poor prognosis, with treatment failure, relapse, or resistance observed even after standard rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone (R-CHOP) therapy; refractory disease remains difficult to manage with current chemotherapeutic regimens.
Persistent relapse despite effective frontline therapy: A substantial proportion of diffuse large B-cell lymphoma (DLBCL) patients relapse despite effective first-line immunochemotherapy, highlighting an unmet need for practical biomarkers beyond existing clinical risk scores to identify at-risk patients earlier.
BTK inhibitor resistance and safety burden: Resistance to Bruton's tyrosine kinase inhibitors (BTKis) is a growing concern, with mutations such as BTK C481S and PLCG2 D334H identified in marginal zone lymphoma (MZL); outcomes following BTKi resistance in MZL remain poorly characterized but are known to be poor in related B-cell malignancies (e.g., mantle cell lymphoma, chronic lymphocytic leukemia). Additionally, as oral agents given continuously until progression, BTKis carry a distinct safety profile — including rash, diarrhea, musculoskeletal and cardiovascular events, and bleeding — necessitating long-term monitoring and attention to polypharmacy.
CAR-T therapy limitations tied to viral reactivation: Cytomegalovirus (CMV) reactivation in seropositive patients receiving CAR-T therapy is strongly associated with treatment failure, linked to reduced peak CAR-T expansion. The precise immunological mechanism — whether driven by direct viral cytopathic effects, T-cell exhaustion, or resource competition (with pre-infusion CMV-specific T-cell precursor frequency as a key driver) — remains undefined, and current predictive models lack the mechanistic granularity needed to guide clinical intervention.
Immune checkpoint blockade constraints: The efficacy of checkpoint inhibitor therapy depends on pre-existing antitumor immunity; defective antigen presentation during T-cell priming can limit generation of tumor-specific T cells required for effective tumor elimination. In a phase Ib trial combining intratumoral selicrelumab (anti-CD40) with intravenous atezolizumab (anti-PD-L1), all four enrolled patients discontinued due to disease progression at the first PET evaluation (end of cycle 3), despite some tumor stabilization or regression short of objective response.
Ongoing unmet need in DLBCL: Collectively, these resistance patterns and mechanistic gaps underscore an urgent need for continued research into novel agents and combination strategies for DLBCL and other R/R B-cell NHL subtypes.
Frequently Asked Questions
References
- [1] Li C, Lu F et al.. Prophylactic antibiotic treatment with TMP-SMX decreased the incidence of interstitial pneumonia in patients with B-cell lymphoma on chemotherapy. BMC cancer. 2020 Aug 8. 32770971
- [2] Nixon S, Duquette D et al.. How We Manage Patients with Indolent B-Cell Malignancies on Bruton's Tyrosine Kinase Inhibitors: Practical Considerations for Nurses and Pharmacists. Current oncology (Toronto, Ont.). 2023 Apr 18. 37185435
- [3] Graf SA, Gopal AK. Idelalisib for the treatment of non-Hodgkin lymphoma. Expert opinion on pharmacotherapy. 2016. 26818003
- [4] Nayak RK, Gerber D et al.. SOHO State of the Art Updates and Next Questions | Immunotherapeutic Options for Patients With Mantle Cell Lymphoma Who Progress on BTK Inhibitors. Clinical lymphoma, myeloma & leukemia. 2023 Dec. 37661513
- [5] Qi T, Guo J et al.. Combination Treatment of Rituximab and Therapeutic Vaccines Affords Superior Tumor Suppression and Relapse Prevention for Non-Hodgkin Lymphoma. Advanced materials (Deerfield Beach, Fla.). 2025 Jul. 40214308
- [6] Palanca-Wessels MC, Czuczman M et al.. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. The Lancet. Oncology. 2015 Jun. 25925619
- [7] Baldi F, Dentone C et al.. Case report: Sotrovimab, remdesivir and nirmatrelvir/ritonavir combination as salvage treatment option in two immunocompromised patients hospitalized for COVID-19. Frontiers in medicine. 2022. 36698815
- [8] Sharp J, Shana'ah AY et al.. Resistance Mechanism for Zanubrutinib in Marginal Zone Lymphoma. Journal of the National Comprehensive Cancer Network : JNCCN. 2025 Jun 23. 40550489
- [9] Nastoupil LJ, Bartlett NL. Navigating the Evolving Treatment Landscape of Diffuse Large B-Cell Lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023 Feb 1. 36508700
- [10] Qiu Y, Yun MM et al.. Combination of cytokine-induced killer and dendritic cells pulsed with antigenic α-1,3-galactosyl epitope-enhanced lymphoma cell membrane for effective B-cell lymphoma immunotherapy. Cytotherapy. 2016 Jan. 26549382
- [11] Liu J, Chang YT et al.. Marine sponge-derived alkaloid inhibits the PI3K/AKT/mTOR signaling pathway against diffuse large B-cell lymphoma. Medical oncology (Northwood, London, England). 2024 Jul 29. 39073639
- [12] Alshatti N, Lemonnier F et al.. Phase I(b) study evaluating the safety and efficacy of intratumoral agonistic anti-CD40 (selicrelumab) in combination with anti-PD-L1 (atezolizumab) in patients with refractory or relapsed B-cell lymphoma (ITSELF trial). Immuno-oncology technology. 2026 Mar. 41502913
- [13] Shen K, Jiang S et al.. Elevated FGR protein expression identifies a high-risk subset of diffuse large B-cell lymphoma and a potential therapeutic target. Frontiers in oncology. 2026. 42078811
- [14] Sridharan P, Ghosh M. A federated digital twin reveals cytomegalovirus reactivation impairs CAR-T cell therapy via IL-15-mediated cytokine competition in B-Cell lymphoma. Frontiers in immunology. 2026. 42367785
- [15] Halcu G, Mureșan FC et al.. PD-L1 Expression and Tumor Microenvironment Dynamics in Diffuse Large B-Cell Lymphoma: Immunophenotypic Insights. Journal of medicine and life. 2025 May. 40599139
- [16] Freytes CO, Loberiza FR et al.. Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry. Blood. 2004 Dec 1. 15280203
- [17] Angelos MG, Ballard HJ et al.. Advances and Personalized Approaches in the Frontline Treatment of T-Cell Lymphomas. Journal of personalized medicine. 2022 Feb 11. 35207754
Contact Us
Address
One Research Ct, Suite 450
Rockville, MD 20850
For General Inquiry
info@pienomial.com
